-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Amphastar Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to 2024.
- Amphastar Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $6M, a 28.4% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was $29.7M, a 6.79% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was $29.7M, a 6.79% decline from 2023.
- Amphastar Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $31.8M, a 35.6% increase from 2022.
- Amphastar Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $23.5M, a 13.8% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)